Stephen Machatha is Chief Development Officer of Aldeyra Therapeutics, Inc.. Currently has a direct ownership of 236,771 shares of ALDX, which is worth approximately $1.25 Million. The most recent transaction as insider was on Aug 12, 2024, when has been sold 16,041 shares (Common Stock) at a price of $4.74 per share, resulting in proceeds of $76,034. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 237K
2.76% 3M change
13.35% 12M change
Total Value Held $1.25 Million

Stephen Machatha Transaction History

Date Transaction Value Shares Traded Shares Held Form
Aug 12 2024
SELL
Open market or private sale
$76,034 $4.74 p/Share
16,041 Reduced 6.35%
236,771 Common Stock
Mar 12 2024
SELL
Open market or private sale
$36,456 $3.16 p/Share
11,537 Reduced 4.52%
243,495 Common Stock
Mar 11 2024
SELL
Open market or private sale
$62,167 $3.41 p/Share
18,231 Reduced 6.67%
255,032 Common Stock
Jul 15 2022
BUY
Grant, award, or other acquisition
-
185,605 Added 40.45%
273,263 Common Stock
Mar 30 2022
BUY
Grant, award, or other acquisition
-
64,395 Added 42.35%
87,658 Common Stock
SM

Stephen Machatha

Chief Development Officer
Lexington, MA

Track Institutional and Insider Activities on ALDX

Follow Aldeyra Therapeutics, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells ALDX shares.

Notify only if

Insider Trading

Get notified when an Aldeyra Therapeutics, Inc. insider buys or sells ALDX shares.

Notify only if

News

Receive news related to Aldeyra Therapeutics, Inc.

Track Activities on ALDX